Climb Bio Announces Positive Initial Phase 1b Data for Budoprutug in Immune Thrombocytopenia

Climb Bio, Inc.

Phase 1b enrolled 15 patients at 250 mg (n=6) and 500 mg (n=9) doses, median follow-up 38 and 12 weeks respectively.
Budoprutug was well tolerated with no serious adverse events, no discontinuations, and all AEs Grade 1-2.
In 250 mg cohort, B-cells depleted by >90% at Week 4; mean platelet count increased by 111,000/µL at Week 24.
Four of six patients achieved durable platelet responses; two had platelet levels ≥100x10^3/µL for over 24 weeks.
Of four patients previously treated with rituximab, three responded to budoprutug, two with durable/complete responses.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.